PHAT is now targeting 25-34 according to analysts. I am not surprised. It has a pipeline and is pending approval for a medication product to treat a stomach bacteria that causes chronic infection and symptoms are often refractory to long and elaborate treatment protocols. The product is already in Asia and doing well in YoY reports. PHAT has partnered with...
TSHA is a gene technology medical company which reported on its clinical trials for Rett Syndrome which is a neurobehavioral disorder separate from others like autism or schizophrenia. This could be a breakthrough medication for those who suffer from Rett. TSHA102 could be heralded as a miracle treatment ( not a cure). Price had trended up in February and...
SRZN has had good momentum. It has no revenues. Clinical trials but a lot of cash. SRZN has advanced trials underway for a product to treat alcoholic hepatitis presumably settling it down before it becomes irreversible cirrhosis (only for patients who are alcohol-free) and also useful for liver metabolic disorders from a genetic basis. SRZN has been...
we are pumping 35%+ in the premarket over our past resistant below the 5$, now is our support , we going to see a potential resistant and selling pressure below 7.80$, if we did we need to see buying pressure happing above the 6.18$, to confirm the breaking for that resistant the next time, and continue to go up to the next price target around the 11.50$. if we...
Clarus Therapeutics Holdings, Inc. (CRXT) Announced Initiation of Phase 4 Clinical Trial of JATENZO, the first and only FDA-approved oral softgel for testosterone replacement therapy in adult male. On 3/31/2022 Serge Belanger from Needham & Company LLC brokerage set a Buy Rating for CRXT and a Price Target of $8.00, which is 9 times higher than the current...
AYTU Aytu BioPharma announced today that the FDA has granted Fast Track designation to AR101, a protein kinase inhibitor, for the treatment of patients with Vascular Ehlers-Danlos Syndrome. After the bullish news, AYTU stock hit the all time low level. 52 Week Range 0.76 - 7.20 LADENBURG THALM has a price target of $14.50 for the stock. I think a reversal is...
On 8/17/2021 Canaccord Genuity brokerage Lower Price Target for SESN giving a Buy rating from $7.00 to $3.00. Sesen Bio (SESN) flagship drug candidate Vicineum, failed to obtain FDA approval, but they will try a second time to get the regulatory go-ahead for the bladder cancer treatment. buying long term calls could be a strategy for this one. volatility is...
Yesterday, JMP Securities Initiated Coverage on Quoin Pharmaceuticals, Ltd. (QNRX) with a Market Outperform rating and a price target of 8usd. Quoin Pharmaceuticals (NASDAQ: QNRX) is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide. This month, QNRX Signed...
Ardelyx, Inc. ARDX yesterday had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year. Since ARDX’s Market Cap is...
SENS Senseonics is waiting for FDA`s approval for the 180-day version of its Eversense CGM system. Eversense can generate as much as $200 million in sales by 2025. HC Wainwright sees a 6usd price target for it. And let`s not forget it`s a meme stock.
Acurx filed a provisional patent application with the U.S. Patent and Trademark Office for use of ibezapolstat to treat C. difficile Infection (CDI) while reducing recurrence of infection and improving the health of the gut microbiome. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The Company...
The FDA is unlikely to approve Ardelyx`s drug for dialysis patients. Ardelyx received a letter from the FDA stating that deficiencies in the information provided had been found that would preclude discussion of approvals Ardelyx has sought. The most likely target is the 1.6usd support line from which it can bounce up.
Well, doesn't this look familiar? ITRM tested is previous level of support AND resistance in a wide channel today. IDK what the sell-off was but I'm guessing the re-entry had something to do with speculation on the FDA data set to come out next month. "At the end of May, Iterum provided an update on its New Drug Application with the U.S. Food and Drug...
I think is ready to liftoff with positive divergence but there is a possibility of another drop on the green line.
have problem with 22 resistance but if break 22 can go to dynamic resistance 34 or static 39. stop loss 12.5
$NNOX had an explosive upside move on Friday. An upside breakout of this ascending triangle gives me the following targets: TG1: 76.50 TG2: 86 TG3: 96.50 Invalidation under: 52.19 Leave some feedback below if you have any! And don't forget to like and follow if you'd like more 👍
FDA phase 3 failure led to a massive dump. As we know, every reaction in the market is an over-reaction, so get in while it is cheap, or wait and see. Maybe selling puts here could be the correct action. Best of luck.